TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify

TScan Therapeutics, Inc.

All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.
Control arm (transplant alone) had 2 relapses at ~6 months and 1 death; only 1 of 8 achieved complete donor chimerism.
Solid tumor: >40 patients screened; ~60% qualify for at least one TCR-T, ~30% eligible for multiplex (T-Plex) therapy.
First 3 solid tumor patients expected to be dosed early May 2024; initial data from singleplex and multiplex cohorts in H2 2024.
Heme: expansion cohorts at Phase 2 dose planned Q3 2024; Phase 1 enrollment completion and 1-year data in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.